Search
Returning search results with filters:
Remove filter for
Category: Health products
Remove filter for
Last updated: 2019
Remove filter for
Type: Health professional risk communication
Clear all
Search filters
Type
Audience
Category
Issue
Last updated
Displaying 1 - 14 of 14 items.
GILENYA (fingolimod) - Risk of Congenital Malformations
GILENYA (fingolimod) - Risk of Congenital Malformations
Starting date:
December 19, 2019
Posting date:…
AlertHealth professional risk communication | 2019-12-19
XELJANZ / XELJANZ XR (tofacitinib) - Risk of Thrombosis
XELJANZ / XELJANZ XR (tofacitinib) - Risk of Thrombosis
Starting date:
December 2, 2019
Posting date:…
AlertHealth professional risk communication | 2019-12-02
ULORIC ® (febuxostat) - Increased Risk of Cardiovascular Fatal Outcomes
ULORIC ® (febuxostat) - Increased Risk of Cardiovascular Fatal Outcomes
Starting date:
November 4, 2019…
AlertHealth professional risk communication | 2019-11-04
LEMTRADA (alemtuzumab) - Risk of Autoimmune Hepatitis, Haemophagocytic Lymphohistiocytosis, and Associated Serious Cardiovascular Reactions
LEMTRADA (alemtuzumab) - Risk of Autoimmune Hepatitis, Haemophagocytic Lymphohistiocytosis, and Associated Serious Cardiovascular Reactions…
AlertHealth professional risk communication | 2019-10-15
Avalon Fetal Monitor - Risk of Inaccurate Ultrasound-Derived Fetal Heart Rate Monitoring
Avalon Fetal Monitor - Risk of Inaccurate Ultrasound-Derived Fetal Heart Rate Monitoring
Starting date:
October 9, 2019…
AlertHealth professional risk communication | 2019-10-09
Tacrolimus and the Risk of Graft Rejection due to Medication Errors: Inadvertent Switching between Different Oral Formulations
Tacrolimus and the Risk of Graft Rejection due to Medication Errors: Inadvertent Switching between Different Oral Formulations…
AlertHealth professional risk communication | 2019-07-22
ALERTEC (modafinil) and the Risk of Congenital Anomalies
ALERTEC (modafinil) and the Risk of Congenital Anomalies
Starting date:
June 20, 2019
Posting date:
June…
AlertHealth professional risk communication | 2019-06-20
Important Safety Information on Alaris Infusion Sets and Alaris 8100 Pump Module - Risk of Over-Infusion
Important Safety Information on Alaris Infusion Sets and Alaris 8100 Pump Module - Risk of Over-Infusion
Starting date…
AlertHealth professional risk communication | 2019-05-30
Important Safety Information on ACTEMRA® (tocilizumab) - Risk of Hepatotoxicity
Important Safety Information on ACTEMRA® (tocilizumab) - Risk of Hepatotoxicity
Starting date:
May 21, 2019…
AlertHealth professional risk communication | 2019-05-21
Intragastric Balloons and Potential Risk of Gastric and Esophageal Perforation, Pancreatitis, and Overinflation
Intragastric Balloons and Potential Risk of Gastric and Esophageal Perforation, Pancreatitis, and Overinflation
Starting…
AlertHealth professional risk communication | 2019-04-17
PrBENLYSTA (belimumab) - Increased Risk of Serious Depression, Suicidal Ideation or Behaviour, or Self-Injury
PrBENLYSTA (belimumab) - Increased Risk of Serious Depression, Suicidal Ideation or Behaviour, or Self-Injury
Starting…
AlertHealth professional risk communication | 2019-04-04
DARZALEX (daratumumab) and Hepatitis B Virus Reactivation
DARZALEX (daratumumab) and Hepatitis B Virus Reactivation
Starting date:
March 25, 2019
Posting date:…
AlertHealth professional risk communication | 2019-03-25
TECENTRIQ® (atezolizumab) - Risk of Immune-Related Myositis
TECENTRIQ® (atezolizumab) - Risk of Immune-Related Myositis
Starting date:
March 13, 2019
Posting date:…
AlertHealth professional risk communication | 2019-03-13
LARTRUVO (olaratumab) - New clinical trial information important to prescribing decisions
LARTRUVO (olaratumab) - New clinical trial information important to prescribing decisions
Starting date:
January 30,…
AlertHealth professional risk communication | 2019-01-30